Biodegradation study of poly(hydroxybutyrate-co-hydroxyvalerate)/halloysite/oregano essential oil compositions in simulated soil conditions.

The aim of this work was to evaluate the influence of halloysite clay nanoparticles - unmodified (Hal) and organically modified (mHal) - and oregano essential oil (OEO), used as an antimicrobial agent in active packaging, on the biodegradation behavior of poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV) films. Five samples were prepared by melt mixing using 3 wt% clay, and 8 wt% and 10.4 wt% OEO. PHBV compositions containing OEO presented the highest rate of biodegradation, achieving 46% of mass loss after aging for 12 weeks in simulated soil. The addition of clay nanoparticles reduced the polymer's biodegradation to 32%. The compositions containing OEO showed a rough and layered surface with visible cracks, indicating degradation occurring through layer-by-layer erosion from the surface. This degradation was confirmed by the chemical changes on the surface of all samples, with a slight decrease in molar masses. The composition containing 8 wt% OEO presented an increase in the crystallization degree as a result of the preferential consumption of amorphous phase, whereas for the compositions containing clay nanoparticles, both crystalline and amorphous regions were degraded at similar rates. Therefore, the combination of additives allows the biodegradation process of PHBV to be controlled for use in the production of active packaging.

Poly(ɛ-caprolactone) and Eudragit E blends modulate the drug release profiles from FDM printlets.

Thermoplastic polymers have been used to produce filaments by hot melt extrusion (HME), which can be applied to obtain 3D printlets by fused deposition modelling (FDM). Poly(ε-caprolactone) (PCL) is a low melting point thermoplastic polymer that provides HME filaments with excellent mechanical and printability properties. However, due to the highly hydrophobic properties of PCL, they afford printlets with slow drug release behaviour. We hypothesized that blending a less hydrophobic polymer, the Eudragit E (EudE), with PCL could be an approach to increase the drug release rate from PCL 3D printlets. PCL and EudE were blended at different proportions, 50:50, 60:40, 70:30, and 80:20 (w/w), to produce HME filaments. They were produced with dexamethasone at 5 % (w/w) and were effectively extruded and printable by FDM, except that composed of 50:50 (w/w). Printlets had homogeneous distribution of their components. Their drug release behaviour was dependent on the ratio of the polymeric blends. The highest EudE ratio (60:40 w/w) afforded printlets showing the highest release rate. Therefore, adding up to 40 % (w/w) of EudE to PCL does not impair the mechanical and printability properties of its HME filaments. This innovative approach is proposed here to modulate the drug release behaviour from PCL printlets.